

Supplementary Table 5. Input parameters for probabilistic sensitivity analysis

Parameter	Distribution	Value	Alpha	Beta
Population characteristics & analysis conditions				
Anti-HCV prevalence in 40s	Beta	0.38%	0.29	74.75
Anti-HCV prevalence in 50s	Beta	0.61%	0.78	127.05
Anti-HCV prevalence in 60s	Beta	1.06%	1.30	121.29
Acceptability of screening	Beta	77.35%	4.89	1.43
Referral rate	Beta	70.0%	6.80	2.91
Acceptability of treatment	Beta	72.8%	6.07	2.27
Awareness of HCV infection	Beta	20.0%	19.80	79.20
HCV RNA positivity in people with anti-HCV	Beta	46.5%	12.91	14.85
Transition probability				
F0 to F1	Beta	0.107	24.03	200.57
F1 to F2	Beta	0.082	22.16	248.05
F2 to F3	Beta	0.117	25.89	195.37
F3 to F4	Beta	0.116	16.87	128.59
F3 to HCC	Beta	0.0073	103.76	14110.16
F4 to DC	Beta	0.048	25.87	513.02
F4 to HCC	Beta	0.053	12.09	216.05
DC to HCC	Beta	0.075	5.30	65.42
DC to LT	Beta	0.023	1.32	56.17
DC to death	Beta	0.118	212.50	1588.37
HCC to LT	Beta	0.04	23.96	575.04
HCC to death	Beta	0.32	16.52	35.11
LT to death	Beta	0.21	23.54	88.56
Post-LT to death	Beta	0.014	193.24	13609.76
SVR (F3) to HCC	Beta	0.00475	0.70	146.15
Cost				
F0–F3	Gamma	472.35	25.00	0.05
F4	Gamma	532.6	25.00	0.05
DC	Gamma	8487.37	5.84	0.000688
HCC	Gamma	10972.06	11.34	0.00
LT	Gamma	79653.85	25.00	0.00
Post-LT	Gamma	7732.57	25.00	0.00
Utility weights				
F0–F3	Beta	0.854	99.03	16.93
F4	Beta	0.737	247.69	88.39
DC	Beta	0.671	45.51	22.32
HCC 1st year	Beta	0.675	280.25	134.93
HCC over 2nd year	Beta	0.428	6.17	8.25
LT	Beta	0.6	23.99	15.99
Post-LT	Beta	0.75	12.77	4.26
SVR	Beta	0.894	78.58	9.32
SVR (F4)	Beta	0.777	129.56	37.18

HCV, hepatitis C virus; HCC, hepatocellular carcinoma; DC, decompensated cirrhosis; LT, liver transplantation; SVR, sustained virologic response.